HER1-VSSP vaccine / Center of Molecular Immunology - LARVOL DELTA

Post SARS-CoV-2 Vaccine Chilblains-like Lesions. (PubMed, J Rheumatol) - "We would like to share ideas on the article, "A Case of Chilblains-like Lesions Post SARS-CoV-2 Vaccine?" Meara et al reported a female case and concluded, "The chilblains-like lesions suggest that she had an antibody response from either 1 vaccine dose or a previous PCR-negative COVID-19 [coronavirus disease 2019] infection."."

Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Immuno-toxicological evaluation of her1 cancer vaccine in non-human primates: a 6-month subcutaneous study. (PubMed, Immunopharmacol Immunotoxicol) - "HER1 vaccine administered subcutaneously (High Dose Group) achieved good IgG antibody titers although lower than the Positive Control group, but with higher ability to inhibit HER1 phosphorylation. This suggests that the alternative of eliminating the use of Montanide in the HER1 vaccine preparation and the using subcutaneous route is feasible."

Journal • Oncology • Ophthalmology • HER-2